Market Newsdesk

HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil

Marseille, France, December 10, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced that it has signed an exclusive distribution agreement with Diagnosticos da America (DASA) SA for Immunoscore® commercialization in Brazil. Oncologists and patients in Brazil will have an easier access to Immunoscore®, a unique diagnostic assay that predicts the risk of recurrence and the response to the chemotherapy regimen of patients with early stage colon cancer. Today, Immunoscore® is available in main Latin American countries (Mexico, Colombia, Argentina and now Brazil) and already used in routine practice in major oncology cancer treatment centers, such as the Institute Fleming in Buenos Aires, Argentina.

DASA has more than 20 thousand employees and 2 thousand doctors, renowned in Brazil and abroad, who work in a robust and capillary health care network across the country.  The company performs more than 275 million exams for 25 million patients per year, through its more than 40 laboratory networks distributed in approximately 800 units. The introduction of Immunoscore® in their panel of innovative testing will accelerate the adoption of our test in Brazil, notably for the triage of early stage colon cancer patients during Covid-19 crisis¹.

“We have been impressed by the capabilities of DASA with a strong footprint in Brazil and a proven record of successes in the highly competitive cancer diagnostics market. This  suggests a rapid ramp up of market penetration for our test in the country ,” says Vincent Fert CEO of HalioDx. He added “We are going to further expand our distribution network worldwide with key players to advocate the introduction of Immunoscore® in the routine practice of oncologists”.

“There are more than 51,000 new cases of Colorectal cancers per year in Brazil² which represent a significant challenge for health organizations in the country. For half of these patients, treatment decisions are problematic leading to over or under treatments. Thanks to Immunoscore®, relapse risk assessment will be improved for early stage colon cancer patients, notably during the Covid-19 crisis where the assay has demonstrated is utility in triaging patients,” commented Dr. Gustavo Aguiar Campana, DASA’s Medical Director. “The partnership between DASA and HalioDx represents a significant advance for Brazilian oncologists in charge of gastrointestinal cancers, ensuring access to precision oncology through an advanced and innovative technology.“

***

About Immunoscore®

Immunoscore® is an in vitro diagnostic test measuring the host immune response at the tumor site. It provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications (³⁴⁵).

In 2020, the World Health Organization (WHO), in its latest edition of the Digestive System Tumours, introduced immune response as an essential and desirable diagnostic criterion for colorectal cancer, in addition to traditional histological parameters.

Subsequently, Immunoscore® was included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localized Colon Cancer.

Immunoscore® Colon is the first IVD diagnostic test of our Immunoscore® portfolio for which a comprehensive corpus of clinical data demonstrating its clinical utility associated with TNM scoring in the management of localized colon cancer has been published. Additional immune-based assays in the same portfolio are used as clinical trial assays to support translational research and clinical development. Those assays enable Multiplex Spatial Tissue Analysis and combine proprietary multiplexed immunohistochemistry, advanced image analysis and computerized algorithms.

Immunoscore® is currently being investigated in a broad number of clinical studies and cancer indications for establishing its performance as a prognostic factor as well as a predictive factor for response to drugs, notably chemotherapies and immunotherapies.

Immunoscore® is commercially available in more than 20 countries.

About HalioDx

HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Leveraging the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions including its flagship Immunoscore® assay for the assessment of the immune contexture of a tumor, as a key determinant of patients’ outcomes and response to cancer treatments.

HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials and the development and commercialization of resulting diagnostic or companion diagnostic tests. Our programs draw on our expertise and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling services, a world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx has rapidly become the preferred partner of Biopharma developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides, and CAR-T cell therapies.

For more information, please visit our websites


www.haliodx.com


and


www.immunoscore-colon.com


and follow the company on


Twitter


,


Linkedin


and


Youtube


.

Immunoscore® is a registered trademark of Inserm licenced to HalioDx. Brightplex®, TMExplore™ and Immunosign® are registered trademarks of HalioDx.

About DASA SA
DASA is the leader in diagnostic medicine in Brazil and Latin America and the 5th largest of the sector in the world, with a focus on clinical analysis, imaging diagnostics, genomics and pathology. The company has a team of more than 24,000 employees and 2,000 doctors, renowned in Brazil and abroad, who work in a robust health care network with cappilarity across the country. Through its more than 40 laboratory brands distributed in about 900 units – such as Delboni Auriemo and Salomão Zoppi (SP), Sérgio Franco and CDPI, (RJ), Exame (DF), among others -, DASA performs more 270 million exams per year. Considered one of the most important health players, DASA works with the purpose of positively impacting people’s health and is committed to be a connecting agent in the sector through a more intelligent, predictive and personalized medicine. In 2019, DASA acquired GSC Integradora de Saúde, with more than 20 years of existence, a reference in Healthcare coordination and management, and Rede Ímpar, the second largest independent hospitalar chain in Brazil, which brings together major hospitals as 9 de Julho (SP), Santa Paula (SP), São Lucas (RJ), CHN (RJ), Brasília Maternity and Hospital (DF) and Águas Claras Hospital (DF).

Contacts

Vincent Fert President and CEO + 33 (0)4 91 29 30 90 [email protected]

ATCG Partners Marie Puvieux / Céline Voisin +33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39 [email protected]

---

¹

O’Connor JM et al, Colorectal Cancer Vol. 9, No. 2.

²

International Agency for Research on Cancer, Globocan 2018.

³

Pagès F et al. Lancet. 2018; 391 (10135)

⁴

Sinicrope FA et al JNCI Cancer Spectrum 2020

⁵

Pagès F et al. Ann Oncol, 2020

Attachment

• PR in English

VANCOUVER, British Columbia, Dec. 10, 2020 (GLOBE NEWSWIRE) — Golden Sky MineralsCorp. (AUEN.V) is pleased to announce results from the inaugural 2020 reverse circulation (RC) drill program at its 100%-owned Hotspot property in the Yukon Territory (see Table 1 for results and Table 2 for collar information).

• Six reverse circulation (RC) holes totalling 568.45m were drilled at the Sure Bet zone. All six holes returned significant near-surface gold (Au) bearing intervals.
• This first pass, shallow-hole drill campaign tested only a 200-metre strike length of the Sure Bet zone which is a 1.7-kilometre-long mineralized structure. An extensive follow-up diamond drill program has been recommended to test the zone at depth and along strike.
• The Hotspot property is a 46.4 km² land package that contains numerous high priority drill targets that will be evaluated in 2021.

      Table 1: Assay results from the 2020 Hotspot RC drill program

Hole ID	From (m)	To (m)	Length (m)	Au (g/t)
HSRC-20-01	32.00	96.01	64.01	0.22
	including
HSRC-20-01	32.00	80.77	48.77	0.26
	including
HSRC-20-01	38.10	44.20	6.10	1.13
HSRC-20-02*	4.57	76.20	71.63	1.34
	including
HSRC-20-02	33.53	39.62	6.09	7.72
	including
HSRC-20-02	33.53	35.05	1.52	20.90

Table 1 (continued):

Hole ID	From (m)	To (m)	Length (m)	Au (g/t)
HSRC-20-03	3.05	27.43	24.38	0.16
HSRC-20-03	35.05	42.67	7.62	0.26
HSRC-20-03	60.96	100.58	39.62	0.39
	including
HSRC-20-03	67.06	86.87	19.81	0.62
	including
HSRC-20-03	82.30	86.87	4.57	1.03
HSRC-20-04	9.14	60.96	51.82	0.14
	including
HSRC-20-04	9.14	24.38	15.24	0.21
HSRC-20-05	4.57	7.62	3.05	0.84
HSRC-20-05	73.15	91.44	18.29	0.37
	including
HSRC-20-05	77.72	88.39	10.67	0.50
HSRC-20-06	3.05	86.87	83.82	0.40
	including
HSRC-20-06	10.67	25.91	15.24	0.64
HSRC-20-06	62.48	86.87	24.38	0.48
	including
HSRC-20-06	62.48	73.15	10.67	0.61

*Of specific note is the exclusion of high-grade overburden intersected in HSRC-20-02. An assay of 17.82 g/t Au over 3.05m was returned from 1.52m to 4.57m, which comprised a mix of strong gold-bearing overburden and bedrock. The source of the high-grade gold values in overburden is undetermined, but warrants follow-up exploration.

Table 2: Drill collar information

Hole ID	Easting	Northing	Azimuth	Dip	Depth (m)
HSRC-20-01	501553	7035531	300	-45	99.06
HSRC-20-02	501494	7035565	120	-50	76.20
HSRC-20-03	501523	7035528	30	-45	100.58
HSRC-20-04	501673	7035631	315	-50	91.44
HSRC-20-05	501463	7035724	45	-50	100.58
HSRC-20-06	501530	7035658	360	-48.5	100.58

LOCATION


:

The Hotspot property is located on the Yukon side of the Yukon-Alaska border, in the North Ladue placer district which has produced >20,000 oz of placer gold. The property is situated along the Big Creek fault, a regional-scale fault system that hosts numerous porphyry and orogenic gold deposits within the Yukon-Tanana Terrane. The closest major prospect to Hotspot is the Taurus copper (Cu) – molybdenum (Mo) – gold (Au) porphyry deposit, located 25 km to the northwest (in Alaska), which has an inferred resource of 68.3 million tonnes grading 0.275% Cu, 0.032% Mo, and 0.166 g/t Au.

MINERALIZATION:

Gold mineralization at Hotspot is hosted by a Tertiary-aged (Eocene, 48-58 Ma) rhyolite pyroclastic tuff. Gold is associated with limonite and pyrite and bears a pathfinder signature indicative of a low-sulphidation epithermal system (silver, antimony, mercury, and arsenic). Rhyolite-hosted low-sulphidation epithermal systems include deposits with significant tonnage such as the Round Mountain deposit (>20M oz gold) and the Sleeper deposit (4.7M oz gold), both in Nevada, USA. In addition to the geological and geochemical settings, the grade and style of gold mineralization show similarities to these deposits.

The Round Mountain deposit is characterized by three styles of gold mineralization: 1) low-grade, high tonnage oxidized ore in a poorly welded tuff; 2) vein-hosted gold along fractures in welded tuffs and sediments, and; 3) bonanza-grade ‘pockets’.

At Hotspot, the widest and most consistently mineralized intercept was returned from HSRC-20-06 (0.40 g/t Au over 83.82m). Oxidation occurred throughout the majority of the hole, with variable concentrations of pyrite (1-5%). Other holes returned sporadic mid-grade gold values within the broad lower grade zones, likely related to veining and fracturing. An example of this occurs in hole HSRC-20-03, which returned 2.26 g/t Au over 1.52m within a broader interval of 0.62 g/t Au over 19.81m (67.06m – 86.87m). Lastly, HSRC-20-02 intersected a “Bonanza-grade” pocket returning 20.9 g/t Au over 1.52m (33.53m – 35.05m).

Of the six holes, three were terminated in low- to mid-grade gold mineralization. Due to the limitations of the equipment, holes were drilled to a maximum of 100 meters, and had a maximum vertical depth of 77 meters. Of interest are anomalous molybdenum values at depth in HSRC-20-04: 171 ppm (0.0171%) Mo over 13.7m (67.1m – 80.8m). This suggests potential for various styles of mineralization at depth.

UNTESTED AREAS:

The drill program followed up on a brief 2020 Phase 1 program which included the collection of 135 soil samples and 22 rock samples. Also, an additional 38 additional quartz claims were staked, bringing the property’s total to 222 claims (4,640 ha). The results of this program indicate the presence of another mineralized zone 1 km to the west, displaying a similar pathfinder signature to the Sure Bet zone (refer to linked map).

In addition to this newly discovered zone, the vast majority of the Sure Bet zone has yet to be drill-tested. Gold-in-soil values up to 0.55 g/t Au are present 1.2 km north of the drilled area. A ground magnetic survey shows a magnetic high feature in this area of the zone, to the northwest of the linear magnetic low (interpreted to be a structural feature) which extends through the drilled area. Future drill programs will be directed at fully testing this area, as well as the rest of the Sure Bet zone.

The Sure Bet zone remains open to the north. Further soil sampling, prospecting, and geophysical surveying will be necessary to explore the extent of mineralization.

Message from
John Newell
, President and CEO:

“
Th
is is a grassroots discovery in an unexplored part of the Yukon. To say the results from this inaugural drill program are exciting is an understatement. We may have a deposit type not yet
seen
in the Yukon on our hands. Although it is early days to be comparing Hotspot to known deposits, the similarities of
Hotspot’s
geology, geochemistry, and gold grades to the aforementioned deposits in Nevada are striking.

The results of the RC drill program make it clear that more information is needed.
Discussions are already in the works for bringing a diamond drill to the property for the 2021 season
to
thoroughly test the Sure Bet zone
and gain more insight to the structur
al
and alteration
settings
associated with this mineralized system.

As with our recent Bull’s Eye property results
, we would
again
like to thank the Yukon Territorial Government and Yukon Geological Survey for funding part of this program through the Yukon Mineral Exploration Program (YMEP). Their support has been instrumental in advancing
Hotspot
and similar programs through the initial exploration phase.”

O
ther

Carl Schulze, P. Geo., Consulting Geologist with Aurora Geosciences Ltd, is a qualified person as defined by National Instrument 43-101, for Golden Sky’s Yukon exploration projects, and has reviewed and approved the technical information in this release.

ON BEHALF OF THE BOARD

John Newell, President and Chief Executive Officer

For new information from the Company’s programs, please visit Golden Sky’s website at www.GoldenSkyMinerals.com or contact John Newell by telephone (604) 568-8807 or by email at [email protected].

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Golden Sky has attempted to identify important factors and risks that could affect Golden Sky and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation: inherent risks involved in the exploration and development of mineral properties; the uncertainties involved in interpreting drill results and other exploration data; the potential for delays in exploration or development activities; the geology, grade and continuity of mineral deposits; the possibility that future exploration, development or mining results will not be consistent with Golden Sky’s expectations; accidents, equipment breakdowns, title and permitting matters; labour disputes or other unanticipated difficulties with or interruptions in operations; fluctuating metal prices; unanticipated costs and expenses; uncertainties relating to the availability and costs of financing needed in the future, including to fund any exploration programs on its projects; that Golden Sky may not be able to confirm historical exploration results and other risks set forth in Golden Sky’s public filings at www.sedar.com. In making the forward-looking statements in this news release, Golden Sky has applied several material assumptions, including the assumption that general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Golden Sky does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

The Company
welcomes CTO Rodger
Seccombe
, co-creator of
HealthTab
to the Board. T
hanks, Bobby Rai
for his service and leadership on
the B
oard of
D
irectors and as President
he takes advisory role
.

VANCOUVER, British Columbia, Dec. 10, 2020 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) announces changes to its board of directors today as the Company continues to make significant progress towards its objective of bringing comprehensive point-of-care testing and reporting solutions for chronic disease and viral infection, including COVID-19, to community pharmacies around the world.

The Board extends a warm welcome to the Company’s CTO and co-founder of HealthTab™, Rodger Seccombe.

“I’m really glad to welcome Rodger to the Board, as he has been such an integral part of the team and important driver of our success,” said Board Chair, David Hall. “We look forward to having his perspective at the table as we execute our plans for growth in 2021.”

Mr. Seccombe brings over 20 years of experience in software and technology, as well as clean energy, having successfully developed and sold multiple ventures throughout his career. In 2014, Mr. Seccombe launched a cloud-based informatics system currently being used by some of the largest medical laboratory networks and instrument manufacturers in North America to help monitor and improve the accuracy of their testing. After recognizing the need for more accurate and accessible point-of-care testing services in the community, Mr. Seccombe, along with his brother, created and pioneered HealthTab™, which was later acquired by Avricore Health in 2017.

Resigning from the board and as President, is Bobby Rai, who led the Company through its transition to become Avricore Health from its previous iteration as a cross-licence drug maker. Mr. Rai demonstrated great vision and tenacity in setting Avricore Health on its path to becoming a world leader in bringing innovations to pharmacy, such as the Company’s point-of-care data sharing technology, HealthTab™.

In 2019, Mr. Rai took the role as President to support the transition of new CEO Hector Bremner, and today, now that this transition is fully executed, he takes a role on the Company’s Advisory Board.

Also joining the Advisory Board is Dr. Sanjeev Goel, founder of Peak Human and practicing physician with Kennedy Medical Centre. Dr. Goel promotes healthy lifestyles through plant-based diets, physical activity, mental health and regenerative medicine. Dr. Goel also works with indigenous communities in Ontario to bring quality medical practice to those communities.

The Company has granted stock options to purchase up to 710,000 common shares of the Company pursuant to its Stock Option Plan to various officers of the Company. Each option is exercisable for a period of five years at an exercise price of $0.08 per common share, subject to regulatory regulations.

About HealthTab
+ RASTR

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab™ test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. Results can be printed in-store or accessed securely online.

Typically, HealthTab™ utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.

As part of this direction for HealthTab™, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities. This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company’s goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

Contact:

Hector Bremner, CEO 604-773-8943
[email protected] 
www.avricorehealth.com 

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Chicago, Dec. 10, 2020 (GLOBE NEWSWIRE) — Encyclopaedia Britannica, purveyors of trusted knowledge for over 250 years , has announced its Story of the Year for 2020 along with a roundup of top stories and events that impacted the world. The selection is entirely data-driven and is based on the volume of article views on Britannica.com along with a significant increase in views over the previous year or, in the case of this year’s story, the previous presidential election cycle.  Britannica’s Story of the Year for 2020 is the electoral college.

The electoral college has historically been a hot topic during presidential elections, and this year was no exception.  With controversy and greater scrutiny around various state electoral college votes, views for the United StatesElectoral College Votes by State spiked significantly on November 2, the day before Election Day in America. Interest remained high over the next several days, increasing 31,468% over searches from the 2016 election. As readers looked for more clarity, the article Electoral College increased 16,546% and How Does the Electoral College Work? saw an uptick of 4,568% from the last election.

“The electoral votes were the key to understanding who would win the election—the most important election of our times, as many called it—and they’re part of a complicated historical institution that can be difficult to understand,” says Erik Gregersen, Senior Editor at Encyclopaedia Britannica. “We’re glad that our content could make it all easier to grasp and give our American readers a better sense of how their own votes count and what role they were playing in determining their country’s future.”

Readers also signaled an interest in learning more about the key figures in this year’s election. On November 7, the day President-elect Joe Biden and Vice President-elect Kamala Harris gave their victory speeches, the biography of Kamala Harris saw the greatest one-day article views of any single biography on Britannica.com for the year and was the most popular for any living individual in all of 2020.

Many other stories captivated the world and stood out in the data for 2020. Britannica’s Year in Review sheds light on stories that sent people in droves to Britannica.com for a closer look at the facts behind events and issues shaping the year. In the weeks following the killing of George Floyd by a Minneapolis police officer and the subsequent unrest in the city, readers immersed themselves in learning more  about the history of police brutality in the United States and protests from years before, including the Los Angeles riots of 1992, with a 23,763% increase, and the Harlem race riot of 1935, with a spike of 37,500%.

People also turned to Britannica to learn more about the lives and accomplishments of prominent Americans lost this past year.  Searches for Kobe Bryant spiked after the tragic death of the NBA legend in January, as did the biographies for Supreme Court Justice Ruth Bader Ginsberg and American civil rights leader John Lewis in reaction to their deaths.

In a year of much uncertainty and angst, many looked for ways to decompress and enjoy time spent at home.  Top searches in the world of entertainment include a 7,715% spike for Alexander Hamilton when the Broadway hit was released on Disney+ and a 18,815% increase for Catherine the Great when Hulu debuted The Great, a television series loosely based on the rise of the Empress of Russia.

“What the data shows is that people are turning time and time again to Britannica to put knowledge into context,” says Gregersen.  “Whether they are tuning in to watch Tiger King on Netflix, thinking about how to best protect themselves and their loved ones from the COVID-19 pandemic, or watching the U.S. presidential election unfold, they rely on the facts and trust the credibility of Britannica. In today’s world, Britannica is more relevant than ever.”  

Read more about Britannica’s 2020 Story of the Year and Year in Review.  

 

 

About the Britannica Group
The Britannica Group is a global knowledge leader. A pioneer in digital learning since the 1980s, the company today serves the needs of students, lifelong learners, and professionals by providing curriculum products, language-study courses, digital encyclopedias, and professional readiness training through its extensive products.

The company has continued to redefine information discovery in the technology and education fields, serving 83 countries and 150 million students worldwide in 16 languages. Britannica’s mission to inspire curiosity and the joy of learning has earned it the ranking of the #1 company to watch in EdTech Digest’s State of the EdTech report for 2019-2020. It is headquartered in Chicago.

For more information, visit corporate.britannica.com and follow @Britannica on Facebook, Twitter, and Instagram.

###

er, and Instagram.

Meghan Lunghi
Encyclopedia Britannica
[email protected]